Lundbeck CEO joins board of directors at Syros Pharmaceuticals

Deborah Dunsire, CEO at Lundbeck, has been appointed to the board of directors at Syros Pharmaceuticals.

Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

A fresh face has joined the board at the US-based biopharmaceutical company Syros Pharmaceuticals in the form of Deborah Dunsire, CEO at Lundbeck, a press release reveals.

"Syros has all the elements for building an enduring company – programs with the potential to set new standards of care for patients, a discovery engine to continue to fuel its pipeline, and great people," Dunsire says in the release, and adds:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs